The cancer burden attributable to biologic agents

Annals of Epidemiology

Volumn 25, Issue 3, 2015, Pages 183-187

  Schottenfeld, David ^a   Beebe Dimmer, Jennifer ^b,c  

^a UNIVERSITY OF MICHIGAN SCHOOL OF PUBLIC HEALTH   (United States)

^b WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c KARMANOS CANCER INSTITUTE   (United States)

Author keywords

Attributable risk; Helicobacter pylori; Hepatitis B; Hepatitis C; Human papillomavirus; Population attributable fraction

Indexed keywords

CARCINOGEN; RECOMBINANT VACCINE; WART VIRUS VACCINE; BIOLOGICAL FACTOR;

ALCOHOL CONSUMPTION; ARTICLE; CANCER INCIDENCE; CANCER PREVENTION; CANCER RISK; CONDYLOMA ACUMINATUM; HELICOBACTER PYLORI; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; LIVER CELL CARCINOMA; MALIGNANT NEOPLASTIC DISEASE; PASSIVE IMMUNIZATION; PREVENTIVE HEALTH SERVICE; PRIMARY PREVENTION; PRIORITY JOURNAL; SMOKELESS TOBACCO; SMOKING; STOMACH CANCER; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA IN SITU; WART VIRUS; ADULT; AGED; COMPLICATION; COST OF ILLNESS; DEVELOPED COUNTRY; DEVELOPING COUNTRY; FEMALE; HEALTH; HEALTH SURVEY; HEPACIVIRUS; INCIDENCE; INFECTION; MALE; MICROBIOLOGY; MIDDLE AGED; NEOPLASMS; PAPILLOMAVIRUS INFECTIONS; PARASITOLOGY; PREVALENCE; RISK; VERY ELDERLY; VIROLOGY;

ADULT; AGED; AGED, 80 AND OVER; BIOLOGICAL FACTORS; COST OF ILLNESS; DEVELOPED COUNTRIES; DEVELOPING COUNTRIES; FEMALE; GLOBAL HEALTH; HELICOBACTER PYLORI; HEPACIVIRUS; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HUMANS; INCIDENCE; INFECTION; MALE; MIDDLE AGED; NEOPLASMS; PAPILLOMAVIRUS INFECTIONS; POPULATION SURVEILLANCE; PREVALENCE; RISK;

EID: 84923313194     PISSN: 10472797     EISSN: 18732585     Source Type: Journal    
DOI: 10.1016/j.annepidem.2014.11.016     Document Type: Article

References (55)

1. Schottenfeld D., Beebe-Dimmer J.L., Buffler P.A., Omenn G.S. Current perspective on the global and United States cancer burden attributable to lifestyle and environmental risk factors. Annu Rev Public Health 2013, 34:97-117.
2. Parkin D.M. The global health burden of infection-associated cancers in the year 2002. Int J Cancer 2006, 118(12):3030-3044.
3. de Martel C., Ferlay J., Franceschi S., Vignat J., Bray F., Forman D., et al. Global burden of cancers attributable to infections in 2008: a review and synthetic analysis. Lancet Oncol 2012, 13(6):607-615.
4. Bruzzi P., Green S.B., Byar D.P., Brinton L.A., Schairer C. Estimating the population attributable risk for multiple risk factors using case-control data. Am J Epidemiol 1985, 122(5):904-914.
5. Spiegelman D., Hertzmark E., Wand H.C. Point and interval estimates of partial population attributable risks in cohort studies: examples and software. Cancer Causes Control 2007, 18(5):571-579.
6. Morgenstern H. Attributable fractions. Encyclopedia of epidemiology 2008, Volume I:55-63. Sage Publications, Thousand Oaks, CA.
7. International agency for research on cancer: a review of human carcinogens, biologic agents volume 100B 2012, 11-48. IARC, Lyon, France.
8. Levin M.L. The occurrence of lung cancer in man. Acta Unio Int Contra Cancrum 1953, 9(3):531-541.
9. Woller N., Kuhnel F. Virus infection, inflammation and prevention of cancer. Viruses and human cancer: from basic science to clinical prevention 2014, 33-58. Springer, Berlin-Heidelberg, Germany. M.H. Chang, K.T. Jeang (Eds.).
10. Schottenfeld D., Beebe-Dimmer J. Chronic inflammation: a common and important factor in the pathogenesis of neoplasia. CA Cancer J Clin 2006, 56(2):69-83.
11. Ferlay J., Shin H.R., Bray F., Forman D., Mathers C., Parkin D.M. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010, 127(12):2893-2917.
12. McGlynn K.A., London W.T. The global epidemiology of hepatocellular carcinoma: present and future. Clin Liver Dis 2011, 15(2):223-243.
13. Altekruse S.F., McGlynn K.A., Reichman M.E. Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005. JClin Oncol 2009, 27(9):1485-1491.
14. El-Serag H.B. Hepatocellular carcinoma. NEngl J Med 2011, 365(12):1118-1127.
15. Bosetti C., Levi F., Boffetta P., Lucchini F., Negri E., La V.C. Trends in mortality from hepatocellular carcinoma in Europe, 1980-2004. Hepatology 2008, 48(1):137-145.
16. Beasley R.P., Hwang L.Y., Lin C.C., Chien C.S. Hepatocellular carcinoma and hepatitis B virus. A prospective study of 22 707 men in Taiwan. Lancet 1981, 2(8256):1129-1133.
17. Beasley R.P. Hepatitis B virus. The major etiology of hepatocellular carcinoma. Cancer 1988, 61(10):1942-1956.
18. Feret E., Larouze B., Diop B., Sow M., London W.T., Blumberg B.S. Epidemiology of hepatitis B virus infection in the rural community of Tip, Senegal. Am J Epidemiol 1987, 125(1):140-149.
19. Chang M.H., Chen D.S., Hsu H.C., Hsu H.Y., Lee C.Y. Maternal transmission of hepatitis B virus in childhood hepatocellular carcinoma. Cancer 1989, 64(11):2377-2380.
20. Tsukuma H., Hiyama T., Tanaka S., Nakao M., Yabuchi T., Kitamura T., et al. Risk factors for hepatocellular carcinoma among patients with chronic liver disease. NEngl J Med 1993, 328(25):1797-1801.
21. Thorgeirsson S.S., Grisham J.W. Molecular pathogenesis of human hepatocellular carcinoma. Nat Genet 2002, 31(4):339-346.
22. Block T.M., Mehta A.S., Fimmel C.J., Jordan R. Molecular viral oncology of hepatocellular carcinoma. Oncogene 2003, 22(33):5093-5107.
23. Perz J.F., Armstrong G.L., Farrington L.A., Hutin Y.J., Bell B.P. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. JHepatol 2006, 45(4):529-538.
24. Mori M., Hara M., Wada I., Yamomoto K., Honda M., Naromoto J., et al. Prospective study of hepatitis B and C viral infections, cigarette smoking, alcohol consumption, and other factors associated with hepatocellular carcinoma risk in Japan. Am J Epidemiol 2000, 151(2):131-139.
25. Peers F., Bosch X., Kaldor J., Linsell A., Pluijmen M. Aflatoxin exposure, hepatitis B virus infection and liver cancer in Swaziland. Int J Cancer 1987, 39(5):545-553.
26. Trichopoulos D., Bamia C., Lagiou P., Fedirko V., Trepo E., Jenab M., et al. Hepatocellular carcinoma risk factors and disease burden in a European cohort: a nested case-control study. JNatl Cancer Inst 2011, 103(22):1686-1695.
27. Colombo M. The role of hepatitis C virus in hepatocellular carcinoma. Recent Results Cancer Res 1998, 154:337-344.
28. Afdhal N., Zeuzem S., Kwo P., Chojkier M., Gitlin N., Puoti M., et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. NEJM 2014, 370(20):1889-1898.
29. Sun C.A., Wu D.M., Lin C.C., Lu S.N., You S.L., Wang L.Y., et al. Incidence and cofactors of hepatitis C virus-related hepatocellular carcinoma: a prospective study of 12,008 men in Taiwan. Am J Epidemiol 2003, 157(8):674-682.
30. Kowdley K.V., Gordon S.C., Reddy K.R., Rossaro L., Bernstein D.E., Lawitz E., et al. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. NEJM 2014, 370(20):1879-1888.
31. Kane M.A., Brooks A. New immunization initiatives and progress toward the global control of hepatitis B. Curr Opin Infect Dis 2002, 15(5):465-469.
32. Chang M.H., You S.L., Chen C.J., Liu C.J., Lee C.M., Lin S.M., et al. Decreased incidence of hepatocellular carcinoma in hepatitis B vaccines: a 20-year follow-up study. JNatl Cancer Inst 2009, 101(19):1348-1355.
33. Kusters J.G., van Vliet A.H., Kuipers E.J. Pathogenesis of Helicobacter pylori infection. Clin Microbiol Rev 2006, 19(3):449-490.
34. Kansau I., Raymond J., Bingen E., Courcoux P., Kalech N., Berguet M., et al. Genotyping of Helicobacter pylori isolates by sequencing of PCR products and comparison with the RAPD technique. Res Microbiol 1996, 147(8):661-669.
35. McColl K.E. Clinical practice. Helicobacter pylori infection. NEngl J Med 2010, 362(17):1597-1604.
36. Fock K.M., Ang T.L. Epidemiology of Helicobacter pylori infection and gastric cancer in Asia. JGastroenterol Hepatol 2010, 25(3):479-486.
37. Perez-Perez G.I., Rothenbacher D., Brenner H. Epidemiology of Helicobacter pylori infection. Helicobacter 2004, 9(Suppl. 1):1-6.
38. Everhart J.E., Kruszon-Moran D., Perez-Perez G.I., Tralka T.S., McQuillan G. Seroprevalence and ethnic differences in Helicobacter pylori infection among adults in the United States. JInfect Dis 2000, 181(4):1359-1363.
39. Siegel R., Naishadham D., Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013, 63(1):11-30.
40. Jemal A., Siegel R., Ward E., Hao Y., Jiaquan X., Murray T., et al. Cancer statistics, 2008. CA Cancer J Clin 2008, 58(2):71-96.
41. Lambert R., Guilloux A., Oshima A., Pompe-Kirn V., Bray F., Parkin M., et al. Incidence and mortality from stomach cancer in Japan, Slovenia and the USA. Int J Cancer 2002, 97(6):811-818.
42. Malvezzi M., Bonifazi M., Bertuccio P., Levi F., La Vecchia C., Decarli A., et al. An age-period-cohort analysis of gastric cancer mortality from 1950 to 2007 in Europe. Ann Epidemiol 2010, 20(12):898-905.
43. Anderson W.F., Camargo M.C., Fraumeni J.F., Correa P., Rosenberg P.S., Rabkin C.S. Age-specific trends in incidence of noncardia gastric cancer in US adults. JAMA 2010, 303(17):1723-1728.
44. Huang J.Q., Sridhar S., Chen Y., Hunt R.H. Meta-analysis of the relationship between Helicobacter pylori seropositivity and gastric cancer. Gastroenterology 1998, 114(6):1169-1179.
45. International agency for research on cancer: a review of human carcinogens, biologic agents volume 100B, human papillomaviruses 2012, 255-313. IARC, Lyon, France.
46. Crosbie E.J., Einstein M.H., Franceschi S., Kitchener H.C. Human papillomavirus and cervical cancer. Lancet 2013, 382(9895):889-899.
47. Palefsky J.M. Human papillomavirus infection and anogenital neoplasia in human immunodeficiency virus-positive men and women. JNatl Cancer Inst Monogr 1998, (23):15-20.
48. Melbye M., Smith E., Wohlfahrt J., Osterlind A., Orholm M., Bergmann O.J., et al. Anal and cervical abnormality in women-prediction by human papillomavirus tests. Int J Cancer 1996, 68(5):559-564.
49. Palefsky J.M., Holly E.A. Molecular virology and epidemiology of human papillomavirus and cervical cancer. Cancer Epidemiol Biomarkers Prev 1995, 4(4):415-428.
50. Chaturvedi A.K., Engels E.A., Pfeiffer R.M., Hernandez B.Y., Xiao W., Kim E., et al. Human papillomavirus and rising oropharyngeal cancer incidence in the United States. JClin Oncol 2011, 29(32):4294-4301.
51. Chaturvedi A.K., Anderson W.F., Lortet-Tieulent J., Curado M.P., Ferlay J., Franceschi S., et al. Worldwide trends in incidence rates for oral cavity and oropharyngeal cancers. JClin Oncol 2013, 31(36):4550-4559.
52. Ryerson A.B., Peters E.S., Coughlin S.S., Chen V.W., Gillison M.L., Reichman M.E., et al. Burden of potentially human papillomavirus-associated cancers of the oropharynx and oral cavity in the US, 1998-2003. Cancer 2008, 113(Suppl. 10):2901-2909.
53. Kahn J.A. HPV vaccination for the prevention of cervical intraepithelial neoplasia. NEngl J Med 2009, 361(3):271-278.
54. Shaw A.R. Human papillomavirus vaccines six years after approval. Annu Rev Med 2013, 64:91-100.
55. Niccolai L.M., Julian P.J., Meek J.I., McBride V., Hadler J.L., Sosa L.E. Declining rates of high-grade cervical lesions in young women in Connecticut, 2008-2011. Cancer Epidemiol Biomarkers Prev 2013, 22(8):1446-1450.